Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1556-1562

  Frase, Hilary ^a   Toth, Marta ^a   Champion, Matthew M ^a   Antunes, Nuno T ^a   Vakulenko, Sergei B ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; BACTERIAL ENZYME; BETA LACTAMASE; CLAVULANIC ACID; GES ENZYME; GLYCINE; SERINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ASPARAGINE; BETA-LACTAMASES; CHROMATOGRAPHY, LIQUID; CLAVULANIC ACID; ENZYME INHIBITORS; GLYCINE; MICROBIAL SENSITIVITY TESTS; SERINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953213321     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01292-10     Document Type: Article

References (43)

1. Ambler, R. P., et al. 1991. A standard numbering scheme for the class A β-lactamases. Biochem. J. 276(Pt. 1):269-270.
2. Bae, I. K., et al. 2007. Genetic and biochemical characterization of GES-5, an extended-spectrum class A β-lactamase from Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 58:465-468.
3. Bonomo, R. A., et al. 2001. Inactivation of CMY-2 β-lactamase by tazobactam: initial mass spectroscopic characterization. Biochim. Biophys. Acta 1547:196-205.
4. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Rev. Microbiol. 14:933-951.
5. Brown, R. P., R. T. Aplin, and C. J. Schofield. 1996. Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry 35: 12421-12432.
6. Bush, K., C. Macalintal, B. A. Rasmussen, V. J. Lee, and Y. Yang. 1993. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37:851-858.
7. Canica, M. M., et al. 1998. Phenotypic study of resistance of β-lactamase-inhibitor- resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276. Antimicrob. Agents Chemother. 42:1323-1328.
8. Cartwright, S. J., and A. F. Coulson. 1979. A semi-synthetic penicillinase inactivator. Nature 278:360-361.
9. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Dixon, M. 1953. The determination of enzyme inhibitor constants. Biochem. J. 55:170-171.
11. Drawz, S. M., and R. A. Bonomo. 2010. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23:160-201.
12. Fisher, J. F., S. O. Meroueh, and S. Mobashery. 2005. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chemical Rev. 105:395-424. (Pubitemid 40351628)
13. Frase, H., Q. Shi, S. A. Testero, S. Mobashery, and S. B. Vakulenko. 2009. Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of β-lactamases. J. Biol. Chem. 284: 29509-29513.
14. Gaynes, R., and J. R. Edwards. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
15. Girlich, D., L. Poirel, and P. Nordmann. 2010. Novel ambler class A carbapenem- hydrolyzing β-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. Antimicrob. Agents Chemother. 54: 328-332.
16. Grace, M. E., K. P. Fu, F. J. Gregory, and P. P. Hung. 1987. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with β-lactamases. Drugs Exp. Clin. Res. 13:145-148.
17. Helfand, M. S., et al. 2003. Understanding resistance to β-lactams and β-lactamase inhibitors in the SHV β-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. 278:52724-52729.
18. Hidron, A. I., et al. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Health Care Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
19. Kesado, T., T. Hashizume, and Y. Asahi. 1980. Anti-bacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics. Antimicrob. Agents Chemother. 17:912-917.
20. Kotsakis, S. D., et al. 2010. GES-13, a β-lactamase variant possessing Lys- 104 and Asn-170 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:1331-1333.
21. Mariotte-Boyer, S., M. H. Nicolas-Chanoine, and R. Labia. 1996. A kinetic study of NMC-A β-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins. FEMS Microbiol. Lett. 143:29-33.
22. Moubareck, C., S. Bremont, M. C. Conroy, P. Courvalin, and T. Lambert. 2009. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob. Agents Chemother. 53:3579-3581.
23. Ostercamp, D. L. 1970. Vinylogous imides. II. Ultraviolet spectra and the application of Woodward's rules. J. Org. Chem. 35:1632-1641.
24. Padayatti, P. S., et al. 2006. Rational design of a β-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 Å crystal structure of wt SHV-1 complex with a penam sulfone. J. Am. Chem. Soc. 128:13235-13242.
25. Papp-Wallace, K. M., et al. 2010. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob. Agents Chemother. 54:890-897.
26. Perez, F., A. Endimiani, K. M. Hujer, and R. A. Bonomo. 2007. The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 7:459-469.
27. Poirel, L., I. Le Thomas, T. Naas, A. Karim, and P. Nordmann. 2000. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44:622-632.
28. Poirel, L., et al. 1999. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob. Agents Chemother. 43:573-581.
29. Poirel, L., et al. 2001. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 45:2598-2603.
30. Poole, K. 2004. Resistance to β-lactam antibiotics. Cell. Mol. Life Sci. 61: 2200-2223.
31. Queenan, A. M., et al. 2000. SME-type carbapenem-hydrolyzing class A β-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother. 44:3035-3039.
32. Rizwi, I., A. K. Tan, A. L. Fink, and R. Virden. 1989. Clavulanate inactivation of Staphylococcus aureus β-lactamase. Biochem. J. 258:205-209. (Pubitemid 19062271)
33. Saves, I., et al. 1995. The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the β-lactamase resistance to clavulanic acid. J. Biol. Chem. 270:18240-18245.
34. Silverman, R. B. 1988. Mechanism-based enzyme inactivation: chemistry and enzymology. CRC Press, Boca Raton, FL.
35. Sulton, D., et al. 2005. Clavulanic acid inactivation of SHV-1 and the inhibitor- resistant S130G SHV-1 β-lactamase. Insights into the mechanism of inhibition. J. Biol. Chem. 280:35528-35536.
36. Vakulenko, S., and D. Golemi. 2002. Mutant TEM β-lactamase producing resistance to ceftazidime, ampicillins, and β-lactamase inhibitors. Antimicrob. Agents Chemother. 46:646-653.
37. Vourli, S., et al. 2004. Novel GES/IBC extended-spectrum β-lactamase variants with carbapenemase activity in clinical enterobacteria. FEMS Microbiol. Lett. 234:209-213.
38. Walsh, T. R. 2008. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis. 21:367-371.
39. Walther-Rasmussen, J., and N. Hoiby. 2007. Class A carbapenemases. J. Antimicrob. Chemother. 60:470-482.
40. Weldhagen, G. F. 2006. GES: an emerging family of extended spectrum β-lactamases. Clin. Microbiol. Newsletter. 28:145-149.
41. Wilke, M. S., A. L. Lovering, and N. C. Strynadka. 2005. β-Lactam antibiotic resistance: a current structural perspective. Curr. Opin. Microbiol. 8:525-533.
42. Yigit, H., et al. 2001. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151-1161.
43. Yigit, H., et al. 2003. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47:3881-3889.